Roche Wins 'Complimentary' Diagnostic Approval With Bladder Cancer Immune Therapy
This article was originally published in The Gray Sheet
Executive Summary
FDA approved Roche's Ventana PD-L1 assay to help identify patients more likely to respond to its Tecentriq drug for bladder cancer. It's approved as a helpful tool, rather than required test, with the drug, but the assay is part of a growing class of diagnostics that are likely to play an important supporting role in a promising and high-growth branch of oncology.
You may also be interested in...
US Approvals Analysis: Stroke Device, IVDs Highlight October FDA Actions
A PFO-closure device was finally approved for stroke in October. Also during the month, important personalized medicine diagnostics approvals and a next-gen robotic system for stent procedures.
Roche's Oncology Drug Strategy Emphasizes Comprehensive Diagnostics
Executives emphasized the role of "comprehensive diagnostics" in its plan to establish a dominant position in immuno-oncology drugs at this years' American Society of Clinical Oncology annual meeting.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.